体外模型在药物性肝损伤的应用进展  

Progress in application of in vitro models in drug-induced liver injury

作　　者：吴宇[1,2] 耿兴超[2] 汪巨峰[2] 李波[1,3] 

机构地区：[1]中国医学科学院北京协和医学院,北京100730 [2]中国食品药品检定研究院国家药物安全评价监测中心,药物非临床安全评价研究北京市重点实验室,北京100176 [3]中国食品药品检定研究院,北京100050

出　　处：《中国新药杂志》2015年第22期2548-2554,共7页Chinese Journal of New Drugs

基　　金：国家“重大新药创制”科技重大专项(2012ZX09302001);药物非临床安全评价研究北京市重点实验室专项

摘　　要：药物性肝损伤(drug-induced liver injury,DILI)是新药研发上市后被撤市或限制使用的主要原因。由于临床表现复杂,发病率低,而且涉及化学药、中草药和膳食补充剂等种类繁多,在临床前药物筛选过程中难以有效发现药物对肝的损伤作用。国内外均在探索和研究能够预测DILI的相关体外模型,本文汇总了当前国内外DILI最新体外模型研究进展,以期为致肝损伤药物早期筛选和评价模型的合理选择提供参考。Drug-induced liver injury （DILI） is a major cause of withdrawal or restriction of marketed drugs. Due to complicated clinical syndrome, low incidence rate and varieties of chemicals, herbal remedies and/ or dietary supplements, the preelinieal studies for drug screening involving the use of animals are difficult to effec- tively reflect liver damage by drugs. Many in vitro models for predicting DILl have been explored and studied in the world. This review encompasses the latest advances of in vitro models at home and abroad so as to provide reference for the earlier screening and assessment of DILl drugs.

关 键 词：药物性肝损伤 体外模型 单层培养 共培养 3D培养 虚拟筛选 

分 类 号：R994.1[医药卫生—毒理学]